sellModerate
Vivo Opportunity, LLC sold $52M of SLNO
owner at SOLENO THERAPEUTICS INC. 1,101,242 shares at an average of $46.95, traded Apr 29, 2024, filed May 1, 2024.
Warning score
42Value
$52M
1,101,242 shares
Holdings after
7,316,851
-13% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +12Role10% owner
- +25Trade size$51.7M at market
- +5Share of holdings soldSold 13% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001213900-24-038343, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 29, 2024 | SOpen-market sale Common Stockindirect: By Vivo Opportunity Fund Holdings, L.P. | -750,000 | $47.80 | $36M | 7,668,093 | May 1, 2024 |
| Apr 30, 2024 | SOpen-market sale Common Stockindirect: By Vivo Opportunity Fund Holdings, L.P. | -351,242 | $45.13 | $16M | 7,316,851 | May 1, 2024 |
Related signals
Other insiders at SOLENO THERAPEUTICS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | SOLENO THERAPEUTICS INC | Michael F. Huang Sr. VP of Clinical Development | $200k 6,582 shares | -14% | |
| 41Moderate | SOLENO THERAPEUTICS INC | Meredith Manning Chief Commercial Officer | $229k 7,522 shares | -10% | |
| 14Weak | SOLENO THERAPEUTICS INC | Patricia C Hirano SEE REMARKS | $317k 3,830 shares | -22% | |
| 0Weak | SOLENO THERAPEUTICS INC | Patricia C Hirano SEE REMARKS | $22k 266 shares | -2% | |
| 28Weak | SOLENO THERAPEUTICS INC | Patricia C Hirano SEE REMARKS | $265k 3,782 shares | -12% | |
| 70Notable | SOLENO THERAPEUTICS INC | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | $47M 699,095 shares | -93% | |
| 40Moderate | SOLENO THERAPEUTICS INC | Patricia C Hirano SEE REMARKS | $11M 156,315 shares | -139% | |
| 50Moderate | SOLENO THERAPEUTICS INC | Michael F. Huang Sr. VP of Clinical Development | $1.0M 14,583 shares | -35% | |
| 58Moderate | SOLENO THERAPEUTICS INC | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | $966k 21,091 shares | -3% | |
| 34Weak | SOLENO THERAPEUTICS INC | Patricia C Hirano SEE REMARKS | $139k 3,030 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.